Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.10 Consensus Target Price from Analysts

Cardiff Oncology, Inc. (NASDAQ:CRDF) has earned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $10.10.

A number of equities research analysts have issued reports on CRDF shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiff Oncology in a report on Wednesday, January 21st. Noble Financial began coverage on Cardiff Oncology in a research note on Monday, January 5th. They issued an “outperform” rating and a $12.00 target price on the stock. Piper Sandler reduced their price target on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Cardiff Oncology in a research report on Wednesday, January 28th. Finally, Wall Street Zen upgraded Cardiff Oncology from a “sell” rating to a “hold” rating in a report on Wednesday.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CRDF. Capital Advisors Wealth Management LLC bought a new stake in shares of Cardiff Oncology during the 4th quarter valued at about $30,000. Tamar Securities LLC purchased a new stake in Cardiff Oncology in the fourth quarter worth about $32,000. Jeppson Wealth Management LLC bought a new stake in Cardiff Oncology during the 3rd quarter valued at approximately $25,000. Brooklyn Investment Group bought a new stake in Cardiff Oncology during the 3rd quarter valued at approximately $26,000. Finally, R Squared Ltd purchased a new position in shares of Cardiff Oncology during the 4th quarter worth approximately $36,000. 16.29% of the stock is currently owned by institutional investors.

Cardiff Oncology Price Performance

Shares of CRDF stock opened at $1.98 on Monday. The business has a 50-day moving average of $2.26 and a 200 day moving average of $2.24. Cardiff Oncology has a 1-year low of $1.48 and a 1-year high of $4.56. The stock has a market capitalization of $135.35 million, a PE ratio of -2.87 and a beta of 1.32.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings data on Tuesday, February 24th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.07. Cardiff Oncology had a negative return on equity of 82.01% and a negative net margin of 7,733.22%.The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.13 million. Analysts anticipate that Cardiff Oncology will post -0.99 EPS for the current year.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.